Quince Therapeutics

NSQ:QNCX · US22053A1079

BiotechnologyX-Small

360° View

Value73

Price/Sales86

Price/Earnings13

Price/Book72

Dividend Yield1

Growth1

Revenue Growth—

Profit Growth76

Capital Growth28

TSR 52w1

Safety18

Leverage70

Liquidity45

Refinancing9

Combined13

Sentiment1

Analyst Opinions1

Pro Holdings5

Opinion Changes20

Market Pulse5

Profile

CountryUSA

IndustryBiotechnology

SizeX-Small

TypePublic Company

ExchangeNASDAQGS

Founded2012

Employees21

Websitequincetx.com

ISINUS22053A1079

Last UpdateApr 2, 2026

Index & Theme

NeurologyImmunologyInflammationChronic DiseasesGeneticsCentral Nervous SystemRespiratoryNeuroscienceGenetic DisorderBiotechnologyHealth CareMedicalPharmaceutical

Description

Quince Therapeutics, Inc. operates as a late-stage biotechnology company that unlock the patient’s own biology for the treatment of rare diseases. The company's proprietary AIDE technology platform is an innovative drug/device combination that uses…

Analysis

Quince Therapeutics's 360° View rank of 4 places it among the weakest overall — better than 4% of its true peers.

It's lagging on growth (1) and reasonably valued (73). On safety it is highly leveraged (18), and the market shows skeptical sentiment (1). Taken together, its Combined rank of 13 reads as among the weakest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Quince Therapeutics with its peers

Cartesian Therapeutics

NMQ:RNAC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tyra Biosciences

NSQ:TYRA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

TriSalus Life Sciences

NMQ:TLSI

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Crescent Biopharma

NAQ:CBIO

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Tectonic Therapeutic

NMQ:TECX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Larimar Therapeutics

NMQ:LRMR

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →